rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Development of Antibody-Based Therapeutics
    sub title: Translational Considerations & Challenges
  name:
    name part: Tabrizi, Mohammad A.
    role:
      role term: editor.
    role:
      role term: edt
    role:
      role term: http://id.loc.gov/vocabulary/relators/edt
  name:
    name part: Bornstein, Gadi G.
    role:
      role term: editor.
    role:
      role term: edt
    role:
      role term: http://id.loc.gov/vocabulary/relators/edt
  name:
    name part: Klakamp, Scott L.
    role:
      role term: editor.
    role:
      role term: edt
    role:
      role term: http://id.loc.gov/vocabulary/relators/edt
  name:
    name part: SpringerLink (Online service)
  type of resource: text
  origin info:
    place:
      place term: si
    date issued: 2018
    edition: 2nd ed. 2018.
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: electronic
    form: electronic resource
    reformatting quality: access
    form: remote
    extent: VIII, 248 p. 106 illus., 87 illus. in color. online resource.
  abstract: With a key focus on recent developments and advances in the field, this book provides in-depth coverage of topics fundamental to the development of targeted therapeutics. The expansion of targeted modalities in rapidly evolving therapeutic areas, such as immune-oncology, and developments with respect to combination therapies, novel technologies, and the therapeutic application of antibody-drug conjugates, are presented. Additionally, the book builds upon topics discussed in the first edition (2012) where recent innovations warrant elaboration. This, the second edition of Development of Antibody-Based Therapeutics: Translational Considerations, represents a comprehensive evaluation of progress in the field, which sits alongside the first edition to inform, in detail, professional and academic researchers, as well as graduate students. Mohammad A. Tabrizi, Ph.D. is a leader in translational sciences as related to development of antibody-based therapeutics. His product development experience spans many therapeutic areas including oncology and inflammatory disease, and his technical expertise includes preclinical pharmacology and safety, preclinical and clinical pharmacokinetics, pharmacodynamics, GLP-compliant bioanalytics, and clinical pharmacology of therapeutic monoclonal antibodies. Gadi Bornstein, Ph.D. has over seventeen years of experience in Oncology R&D with an emphasis in preclinical antibody discovery and development. Dr. Bornstein currently leads and directs biologics discovery efforts at TESARO. He received his B.S. in biochemistry at the University of California, Davis and his doctoral degree in biochemistry at the University of Southern California Keck School of Medicine. Dr. Bornstein completed his postdoctoral training at Stanford University in the Division of Immunology and Rheumatology. Following his postdoctoral training, Dr. Bornstein joined Amgen Fremont, Inc. (formerly Abgenix, Inc.) as a Staff Scientist in the Preclinical Oncology department. Dr…
  table of contents: 1. Introduction -- 2. Translational Considerations and Challenges: An Overview -- 3. Considerations for Construct and Affinity Design Goals -- 4. Epitope Characterization and Isotype Selection -- 5. Biophysical Considerations for Development of Antibody-Based Therapeutics -- 6. Novel Technologies for Generation of Bispecific Constructs -- 7. Stimulus-Response Mechanisms: An Overview -- 8. Evaluation of Tumor Growth Inhibition in Preclinical Tumor Models -A Quantitative Approach -- 9. Application of Proof-of-Mechanism Biomarkers (POM) in Design and Development of Biologics Modalities -- 10. Antibody Drug Conjugates: Translational Considerations -- 11. Application of PK-PD Modeling and Simulation Approaches for Immuno-Oncology Drugs -- 12. Translational Biomarkers: Application in the Clinical Development of Combination Therapies.
  note: edited by Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp.
  subject:
    topic: Pharmacy
  subject:
    topic: Pharmacology
  subject:
    topic: Biochemistry
  subject:
    topic: Pharmacy
  subject:
    topic: Pharmacology/Toxicology
  subject:
    topic: Biochemistry, general
  classification: RS1-441
  classification: 615.1
  related item:
    title info:
      title: Springer eBooks
  identifier: 9789811304965
  identifier: https://doi.org/10.1007/978-981-13-0496-5
  record info:
    record creation date: 180911
    record change date: 20191026111451.0
    record identifier: 978-981-13-0496-5